rituximab,tazemetostat,lenalidomide
epizyme,eisai
['symphony-1']
check out symphony-1 at #ash22! combination therapy taz+r2 demonstrated a consistent and manageable safety profile while maintaining efficacy in pts with r/r fl who have completed 1 prior systemic therapy. what data are you most excited to see from the upcoming phase 3 portion? 